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Invasive fungal infections (IFI) are a major cause of morbidity and mortality in critically ill patients. Candida spp. infections are the most frequent fungal infections in the Intensive Care Unit (ICU), 
ranking the third most common isolated pathogen and the fourth most 
common cause of nosocomial bloodstream infection (1-3). Attributable 
mortality due to Candida spp. infections ranges from about 42 to 63% 
(4, 5). Several observational studies described a strict correlation be-
tween an early adequate antifungal treatment and reduced mortality in 
critically ill patients with fungal infections (6, 7). However, the defini-
tive diagnosis of fungal infections, based on microbiological identifica-
tions, requires several days and usually occurs late in the clinical course 
(8).
For nearly 30 years, clinicians and researchers have tried to prevent and 
treat early IFI in critically ill patients (9). Three antifungal strategies have 
been used in clinical practice for these purposes: 1) ‘prophylaxis’ defined 
as the administration of antifungal agents in patients without proven or 
suspected fungal infections but with risk factors for its development (e.g. 
fungal colonization, central venous catheter, parenteral nutrition, dialysis, 
abdominal surgery, broad spectrum antibiotics); 2) ‘empiric treatment’ 
defined as antifungals administration triggered by signs and symptoms of 
infection in patients at risk for IFI; 3) ‘pre-emptive treatment’ defined as 
treatment triggered by microbiological evidence of fungal infection, with-
out definitive microbiological identification (e.g. positive biomarkers such 
as 1-3-beta-D-glucan, mannan-antimannan antibodies, procalcitonin); 
(10, 11). The common point of these strategies is that they are ‘untargeted 
treatments’ since they are not driven by an established diagnosis of IFI. In 
clinical practice, it is not always easy to clearly differentiate these strategies, 
which are used in patients with a different grade of probability of fungal 
infection. 
The number of patients potentially treated with antifungals without IFI di-
agnosis is high. In a 1-day cross-sectional multicentre cohort study, Azoulay 
et al. demonstrated that 7.5% of patients admitted to 129 participating ICU 
were receiving systemic antifungal drugs. Two-third of these patients had no 
documented invasive fungal infection (12).
First randomized controlled trials (RCTs) globally showed a reduction in the 
incidence of IFI and mortality with the administration of azoles in both sur-
Main topic of this debate will be "untargeted an-
tifungal treatment".
Should we start antifungal treatment before the 
IFI diagnosis? If yes, which criteria? 
Are there indeed any criteria for starting empiri-
cal antifungal treatment in icu patients?
What has the experience in the antifungal treat-
ment has shown us? any change of the paradig-
mas?
Another question may be: "which antifungal"? 
(there is a -almost commercial-competition).
What is the duration of antifungal treatment?
What is the role of these issues on morbidity, mor-
tality and cost?
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gical and medical critically ill patients (13) and contributed to the 
widespread use of not-targeted antifungal approaches. However, 
subsequent large multicentre RCTs did not confirm these results. 
Schuster et al. (14) randomized 270 critically ill patients with fever 
despite administration of broad-spectrum antibiotics to fluconazole 
or placebo and did not find any difference in terms of mortality or 
incidence of IFI. Ostrosky-Zeichner et al. (15) randomly assigned 
222 patients with at least 3 days of ICU stay and risk factors for 
fungal infections to receive caspofungin or placebo. The incidence 
of proven/probable IFI and mortality were not significantly differ-
ent between the two groups. In another multicenter RCT, Knitsch 
et al. (16) enrolled 252 critically ill patients with localized/general-
ized intra-abdominal infection either of community or of nosoco-
mial origin requiring emergency surgery. They were randomized to 
receive micafungin or placebo. The study was unable to provide any 
significant difference in terms of invasive candidiasis or mortality 
between groups.
Recently, a Cochrane systematic review investigated the effect 
of prophylaxis, pre-emptive and empiric antifungal treatment 
with any antifungal drug (untargeted antifungal treatment) in 
non-neutropenic critically ill patients (9). The review included 22 
RCTs and 2761 patients. There was moderate quality of evidence 
that untargeted antifungal treatment did not significantly reduce 
mortality (RR 0.93, 95% CI 0.79 – 1.09), whereas the risk of 
IFI was significantly reduced by about 45% with low quality of 
evidence (RR 0.57, 95% CI 0.39 – 0.83). Most of the included 
trials investigated prophylaxis or empiric treatment. In subgroup 
analysis, neither prophylaxis nor empiric treatment was associated 
with significant mortality reduction (17). Very recently, another 
multicenter RCT confirmed these results. In the EMPIRICUS 
trial, Timsit et al. (18) enrolled 260 non-neutropenic critically 
ill patients with ICU-acquired sepsis, multiple Candida coloni-
zation, multiple organ failure, exposed to broad-spectrum anti-
biotics. Patients were randomized to receive empirical antifungal 
treatment with micafungin or placebo. The primary outcome was 
survival without proven IFI at 28 days after randomization and it 
was not significantly different between the two groups. Interest-
ingly, the use of empirical micafungin reduced the incidence of 
IFI compared to placebo. 
The most recent clinical practice guideline for the management of 
candidiasis by the Infection Disease Society of America (IDSA) 
stated that empiric antifungal treatment with an echinocandin 
should be considered in critically ill patients with risk factors and 
no other cause of fever, whereas it should be started as soon as 
possible in patients with risk factors and septic shock (19). No-
tably, a ‘strong recommendation’ and moderate quality evidence 
supports these statement. Regarding intra-abdominal candidiasis, 
IDSA recommendation underlined that empiric treatment should 
be considered in patients with clinical evidence of intra-abdom-
inal infection and significant risk factors for candidiasis, such 
as recent abdominal surgery, anastomotic leakage or necrotiz-
ing pancreatitis (strong recommendation; moderate-quality evi-
dence). It should be underlined that IDSA did not take into ac-
count, for timing reason, the evidence from most recent RCTs 
and Cochrane review. 
From available evidence, a paradox arises: the use of antifungal 
drugs before definitive diagnosis of infection in non-neutropenic 
critically ill patients is able to reduce the incidence of IFI with-
out any mortality benefit (20). This should bring us to rethink 
the pathophysiology of fungal infections in ICU patients and to 
consider other forms of antifungal strategies for future trials (21). 
On clinical grounds, a widespread use of untargeted antifungal 
treatment is no longer justified. A case-by-case decision based on 
grade of probability of the infection, risk factors, available bio-
markers and balancing potential benefit with costs and risk of 
increasing resistance may be the most reasonable answer to the 
title question.
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